Chemed’s stock has quietly outperformed the S&P 500 over the past six months, but deeper analysis reveals a company moving at a glacial pace—just 4% revenue growth and 2.8% EPS growth over five years, with declining ROIC. While reasonably valued, there’s little to excite investors, and better opportunities lurk elsewhere, especially in aerospace.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
